buserelin acetate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
buserelin acetate: clinical details
Prescribing considerations
- Use fertility treatment only under a clinician experienced in assisted reproduction; assess ovarian-hyperstimulation risk, particularly with polycystic ovaries.
- For prostate cancer, anticipate the initial testosterone flare, especially with spinal or other high-risk metastases.
- Assess depression history, cardiovascular and diabetes risk, blood pressure, QT risk, anaemia risk and osteoporosis risk.
- Consider benzyl-alcohol accumulation in significant hepatic or renal impairment.
Contraindications and cautions
- Hypersensitivity to buserelin, LHRH/GnRH analogues or product excipients.
- Suprefact: hormone-insensitive tumour or previous bilateral orchiectomy.
- Suprecur/Buserelin fertility injection: undiagnosed vaginal bleeding.
- Pregnancy and breastfeeding.
Monitoring
- Prostate cancer: symptoms, PSA and serum testosterone; assess for early tumour flare.
- Fertility treatment: biochemical and ultrasound response, with active surveillance for ovarian hyperstimulation.
- Blood pressure and glucose where relevant.
- Bone mineral density during prolonged suppression or when osteoporosis risk is increased.
- Mood, cardiovascular status, anaemia risk and ECG/QT factors as clinically indicated.
Clinical pharmacology
Buserelin is a synthetic peptide GnRH agonist. Initial receptor stimulation is followed by pituitary receptor down-regulation and suppression of the hypothalamic–pituitary–gonadal axis. After subcutaneous administration, systemic availability is high; the peptide is inactivated by peptidases in the liver, kidneys and pituitary.
Formulation and product differences
- Both selected products are clear, colourless, sterile multidose solutions for subcutaneous injection containing benzyl alcohol.
- Suprefact injection is licensed for advanced hormone-dependent prostate cancer.
- Suprecur/Buserelin injection is licensed for pituitary desensitisation before gonadotrophin ovulation induction.
- Opened vials should be discarded within the product-specified in-use period and protected from light; do not freeze.
buserelin acetate preparations and strengths
Injection
Route: Parenteral
Strengths: 1 mg/mL
buserelin acetate interactions
Review all prescribed, over-the-counter and complementary products before treatment.
Antidiabetic medicines
Buserelin can weaken glucose-lowering effects, so diabetic control may deteriorate and require closer monitoring.
QT-prolonging medicines
Antiarrhythmics such as quinidine, disopyramide, amiodarone or sotalol, and medicines such as methadone, moxifloxacin or some antipsychotics, may add to the risk of serious rhythm disturbance.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.